Puente A E, Rodenbough J, Orrell T D
Department of Psychology, University of North Carolina at Wilmington 28403-3297.
Int J Neurosci. 1993 Oct;72(3-4):193-200. doi: 10.3109/00207459309024108.
Four groups of 20 each (chronic brain-damaged schizophrenics, chronic non-brain-damaged schizophrenics, chronic non-brain-damaged with "acute" exacerbation, and control subjects) were individually administered Form I of the Luria Nebraska Neuropsychological Battery (LNNB). Control subjects scored significantly lower than all clinical groups on all scales except for the chronic non-brain-damaged schizophrenics on the Reading Scale. "Acute" schizophrenics scored higher on Motor, Visual, Receptive Speech, Intellectual Processes, Pathognomonic, Right Hemisphere and Profile Elevations scales than the other clinical groups. Chronic brain-damaged schizophrenics scored significantly higher than chronic non-brain-damaged schizophrenics on the Profile Elevation scale. To examine the possibility that LNNB performance of the schizophrenic groups may have been related to neuroleptic medication, analyses were completed on the relationship between medication levels and LNNB scores. These results suggested that while the three clinical groups differed in their chlorpromazine equivalents (CPZE), LNNB scores were not related to CPZE dosage.
四组,每组20人(慢性脑损伤精神分裂症患者、慢性非脑损伤精神分裂症患者、伴有“急性”加重的慢性非脑损伤患者和对照组)分别接受了鲁利亚-内布拉斯加神经心理成套测验(LNNB)的第一版测试。除了慢性非脑损伤精神分裂症患者在阅读量表上的得分外,对照组在所有量表上的得分均显著低于所有临床组。“急性”精神分裂症患者在运动、视觉、接受性言语、智力过程、特征性、右半球和剖面图升高量表上的得分高于其他临床组。慢性脑损伤精神分裂症患者在剖面图升高量表上的得分显著高于慢性非脑损伤精神分裂症患者。为了检验精神分裂症组的LNNB表现可能与抗精神病药物治疗有关的可能性,对药物水平与LNNB得分之间的关系进行了分析。这些结果表明,虽然三个临床组的氯丙嗪等效剂量(CPZE)不同,但LNNB得分与CPZE剂量无关。